NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$25.59 +0.01 (+0.04 %)
(As of 08/19/2018 05:25 AM ET)
Previous Close$25.59
Today's Range$24.94 - $25.63
52-Week Range$24.63 - $64.56
Volume1.27 million shs
Average Volume1.33 million shs
Market Capitalization$1.93 billion
P/E Ratio-5.32
Dividend YieldN/A
Beta1.76
Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers. It is also developing PRT2761, which is in Phase 2 for allergic conjunctivitis; and PCSK9 inhibitor in pre-clinical study for hypercholesterolemia. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Debt-to-Equity Ratio0.91
Current Ratio6.69
Quick Ratio6.59

Price-To-Earnings

Trailing P/E Ratio-5.32
Forward P/E Ratio-4.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.55 million
Price / Sales75.00
Cash FlowN/A
Price / CashN/A
Book Value$5.36 per share
Price / Book4.77

Profitability

EPS (Most Recent Fiscal Year)($4.81)
Net Income$-286,090,000.00
Net Margins-1,503.29%
Return on Equity-111.64%
Return on Assets-66.00%

Miscellaneous

Employees252
Outstanding Shares66,090,000
Market Cap$1.93 billion

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) posted its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($1.49) by $0.12. The biopharmaceutical company earned $4.01 million during the quarter, compared to analyst estimates of $6.35 million. Portola Pharmaceuticals had a negative net margin of 1,503.29% and a negative return on equity of 111.64%. Portola Pharmaceuticals's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.22) EPS. View Portola Pharmaceuticals' Earnings History.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Portola Pharmaceuticals.

What price target have analysts set for PTLA?

7 brokerages have issued 1-year target prices for Portola Pharmaceuticals' shares. Their forecasts range from $28.00 to $75.00. On average, they anticipate Portola Pharmaceuticals' stock price to reach $51.40 in the next year. This suggests a possible upside of 100.9% from the stock's current price. View Analyst Price Targets for Portola Pharmaceuticals.

What is the consensus analysts' recommendation for Portola Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Portola Pharmaceuticals.

What are Wall Street analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (8/11/2018)
  • 2. Cowen Inc analysts commented, "Rhythm reported 2Q18 financial results yesterday and we spoke w/ mgmt for an update. As a reminder, the company completed enrollment of both setmelanotide Phase 3 trials in POMC and LepR Deficiency patients in Jun 2018. Mgmt reiterated guidance for results from these trials in 3Q19. We expect positive outcomes based on Phase 2 data. Encouraging long-term Phase 2 data in Bardet-Biedl (BBS) and initial Phase 2 data in Alstrom, POMC Heterozygous, and POMC Epigenetic were announced earlier this year and mgmt reiterated plans to start a single Phase 3 trial w/ both Bardet-Biedl and Alstrom patients in 2H18. Demonstration of consistent impact on appetite and weight across several genetic obesity diseases in 2Q18 has increased our conviction. BUY." (8/9/2018)

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:
  • Mr. William Lis, CEO of Technical Operations & Director (Age 54)
  • Ms. Mardi C. Dier, Interim Co-Pres & CFO (Age 54)
  • Dr. John T. Curnutte, Interim Co-Pres and Head of R&D (Age 66)
  • Mr. Tao Fu, Chief Commercial & Bus. Officer and Exec. VP (Age 46)
  • Dr. John H. Lawrence III, M.D., Sr. VP & Chief Medical Officer (Age 60)

Has Portola Pharmaceuticals been receiving favorable news coverage?

News coverage about PTLA stock has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a news and rumor sentiment score of 0.12 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Portola Pharmaceuticals.

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.98%), Temasek Holdings Private Ltd (7.83%), Partner Fund Management L.P. (7.69%), Cadian Capital Management LP (3.46%), Zevenbergen Capital Investments LLC (1.90%) and Kornitzer Capital Management Inc. KS (1.77%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Which institutional investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Pinnacle Associates Ltd., California Public Employees Retirement System, Alps Advisors Inc., Alps Advisors Inc., Alps Advisors Inc., Strs Ohio and Partner Investment Management L.P.. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include Henry Ward Wolff, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Which institutional investors are buying Portola Pharmaceuticals stock?

PTLA stock was purchased by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, BlackRock Inc., Zevenbergen Capital Investments LLC, Wells Fargo & Company MN, Tocqueville Asset Management L.P., Highland Capital Management LP, Temasek Holdings Private Ltd and Voya Investment Management LLC. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $25.59.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $1.93 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Featured Article: Google Finance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.